Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
Sign Up to like & getrecommendations! Published in 2021 at "Neuropsychopharmacology Reports"
DOI: 10.1002/npr2.12180
Abstract: Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify®). The drug was approved for this indication in the United States in 2002 and has… read more here.
Keywords: receptor partial; disorder; dopamine receptor; partial agonists ... See more keywords
Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01189-8
Abstract: Bipolar disorder is a chronic, disabling, and costly illness with frequent relapses and recurrences, high rates of co-morbid conditions, and poor adherence to treatment. Mood stabilizers and antipsychotics are the cornerstones of treatment. Dopamine receptor… read more here.
Keywords: receptor partial; treatment; partial agonists; bipolar disorder ... See more keywords
The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in special populations.
Sign Up to like & getrecommendations! Published in 2021 at "Psychiatria polska"
DOI: 10.12740/pp/140287
Abstract: D2/D3 dopamine receptor partial agonists (aripiprazole, brexpiprazole, cariprazine) are increasingly often used in the treatment of mental disorders due to a more favourable tolerability profile as compared to other antipsychotics. The article presents the position… read more here.
Keywords: position statement; partial agonists; receptor partial; dopamine receptor ... See more keywords
A1 Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2020.625134
Abstract: Adenosine is an endogenous autacoid that exerts a variety of physiological effects by interacting with cell surface G-protein-coupled receptor subtypes, namely A1, A2A, A2B, and A3 adenosine receptors (ARs) (Borea et al., 2018). Numerous experimental… read more here.
Keywords: receptor partial; adenosine receptor; allosteric modulators; partial agonists ... See more keywords